Bicara insider plans $396K sale of 17,500 shares

Insider Ryan Cohlhepp filed a Form 144 to potentially sell 17,500 BCAX shares after selling 47,500 shares in the prior three months.

Rhea-AI Filing Summary

Bicara Therapeutics Inc. (BCAX) insider Ryan Cohlhepp filed a Form 144 notice covering a proposed sale of 17,500 shares of common stock through UBS Financial Services Inc., with an estimated aggregate value of $396,200.00, expected on September 8, 2026 on NASDAQ.

The notice also lists prior sales of Bicara common stock by Ryan Cohlhepp over the past three months totaling 47,500 shares for aggregate proceeds of $1,357,661.48.

Key Figures

Proposed shares to be sold: 17,500 shares Estimated value of proposed sale: $396,200.00 Shares sold past three months: 47,500 shares +3 more

6 metrics

Proposed shares to be sold 17,500 shares Common stock sale planned for September 8, 2026 under Form 144

Estimated value of proposed sale $396,200.00 Aggregate market value of 17,500 BCAX shares to be sold

Shares sold past three months 47,500 shares Total BCAX common shares sold by Ryan Cohlhepp in three reported transactions

Aggregate proceeds past three months $1,357,661.48 Total proceeds from BCAX sales on July 8, 9 and August 10, 2026

July 8, 2026 sale 28,214 shares for $817,584.36 BCAX common stock sold by Ryan Cohlhepp

August 10, 2026 sale 18,750 shares for $524,533.12 BCAX common stock sold by Ryan Cohlhepp

Key Terms

Form 144, Rule 144, attorney-in-fact, Exercise of Stock Option

4 terms

Form 144 regulatory

"144: Filer Information Filer CIK | Filer CCC"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

attorney-in-fact regulatory

"Signature | /s/ UBS Financial Services Inc., as attorney-in-fact for Ryan"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Exercise of Stock Option financial

"Common | 09/08/2026 | Exercise of Stock Option | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 144 filing disclose for Bicara Therapeutics Inc. (BCAX)?

The filing discloses that insider Ryan Cohlhepp intends to sell up to 17,500 shares of BCAX common stock, with an estimated value of $396,200.00, through UBS Financial Services Inc. on or about September 8, 2026 on NASDAQ.

How many BCAX shares is Ryan Cohlhepp proposing to sell under this Form 144?

Ryan Cohlhepp is proposing to sell 17,500 shares of Bicara Therapeutics Inc. common stock, with an estimated aggregate value of $396,200.00, in a transaction dated September 8, 2026 through UBS Financial Services Inc..

What prior BCAX stock sales by Ryan Cohlhepp are reported in the last three months?

The notice reports three prior sales: 28,214 shares for $817,584.36 on July 8, 2026; 536 shares for $15,544.00 on July 9, 2026; and 18,750 shares for $524,533.12 on August 10, 2026.

What is the total value of BCAX shares sold by Ryan Cohlhepp in the past three months?

According to the notice, Ryan Cohlhepp sold a total of 47,500 shares of Bicara Therapeutics common stock over the past three months for aggregate proceeds of $1,357,661.48, across three transactions in July and August 2026.

How are the new BCAX shares being acquired for sale under the Form 144?

The Form 144 states that the 17,500 shares of Bicara Therapeutics common stock to be sold on September 8, 2026 will come from the exercise of a stock option, with the issuer listed as the source and consideration described as Cash.

Who is acting on behalf of Ryan Cohlhepp in the Form 144 for BCAX?

The signature block identifies UBS Financial Services Inc. signing as attorney-in-fact for Ryan Cohlhepp, indicating UBS is authorized to act on his behalf for this Form 144 notice regarding Bicara Therapeutics Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:04 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:04 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034665
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Cohlhepp Ryan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th Floor New York NY 10010	17500	396200.00	66172934	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2026	Exercise of Stock Option	Issuer			17500	09/08/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ryan Cohlhepp 116 HUNTINGTON AVENUE, SUITE 703 Boston MA 02116	Common	07/08/2026	28214	817584.36
Ryan Cohlhepp 116 HUNTINGTON AVENUE, SUITE 703 Boston MA 02116	Common	07/09/2026	536	15544.00
Ryan Cohlhepp 116 HUNTINGTON AVENUE, SUITE 703 Boston MA 02116	Common	08/10/2026	18750	524533.12

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc., as attorney-in-fact for Ryan Cohlhepp
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)